Kodiak’s Zenkuda Matched Eylea in Phase 3, a Win Against the Dose Regeneron Is Already Leaving Behind
Kodiak Sciences more than doubled after Zenkuda matched Eylea in Phase 3. The comparator was Eylea every eight weeks, not Eylea HD or Vabysmo.
Section
Healthcare technology coverage from BusinessTech News. AI in diagnostics, drug discovery, electronic health records, telehealth platforms, and the medical-device industry. Reporting on Eli Lilly, Pfizer, Novo Nordisk, UnitedHealth, and the venture-backed startups (Tempus, Recursion, Hims) competing for healthcare budgets. Coverage of FDA approvals, CMS reimbursement decisions, and the policy fights over drug pricing, GLP-1 access, and digital-therapeutics adoption.
Kodiak Sciences more than doubled after Zenkuda matched Eylea in Phase 3. The comparator was Eylea every eight weeks, not Eylea HD or Vabysmo.



Eli Lilly crushed Q1 2026 estimates, with Mounjaro revenue up 125% to $8.7 billion…
California patients sue Sutter Health and MemorialCare over AI recording medical visits without consent,…